Scott Smythe, CPA Pharmaceutical Industry Veteran to Head Finance Team
July 12, 2021 – Essex Junction, VT: Haematologic Technologies (“HT”), a global leader in integrated large molecule analytical CRO services, plasma protein reagents, and custom collection devices, announced Scott Smythe, CPA, as Chief Financial Officer. Scott assumes leadership of the finance team and will support the next phase of the Company’s growth by implementing critical systems and best practices needed to establish Haematologic Technologies as an industry leader.
“We are thrilled to have an industry veteran with the experience Scott brings to lead our finance organization,” said David Sunseri, Ph.D., President and Chief Executive Officer. “Scott knows our industry and has the experience implementing financial and accounting systems and controls as well as integrating acquisitions that are essential to our future success. Scott’s experience at Pfizer is well aligned with our current and future organization needs.”
Scott formerly served as Finance Director for Pfizer, Inc., a Fortune 100 Pharmaceutical company, and came to HT with over 25 years of experience. Scott brings a wealth of knowledge and expertise to HT in implementing financial systems, establishing methods of control, integrating acquisitions, developing sound forecasting practices and business processes. Scott enjoyed a career with Pfizer consisting of positions of progressive responsibility from audit through site Controller of a primary manufacturing site, and finally as Finance Director.
Before joining Pfizer, Scott was Controller and Chief Financial Officer for Fisher Hotels Group in New York. Scott began his career as a Senior Auditor with PricewaterhouseCoopers. Scott is a Certified Public Accountant, received his MBA in Accounting from Rutgers University and holds a Bachelor of Arts degree in Chemistry from the University of Colorado.
“Haematologic Technologies has a well-established reputation as an industry-leading Contract Research Organization dedicated to analytical services of large molecules, as well as a highly regarded manufacturer of plasma proteins, antibodies, and custom collection devices,” said Smythe. “I’m excited to come into the company at this time and help establish the key systems needed to support the company’s accelerated growth and helping our customers bring life-changing and life-saving therapies to patients.”
Nearly three decades ago, HT began operations as a research reagents company. With deep expertise in coagulation and hemostasis, we provided highly purified plasma proteins and antibodies to research labs around the world. Soon, biopharma customers began utilizing HT’s analytical and purification services around both native and recombinant therapeutics. Today, HT is well-known for our deep protein chemistry expertise, integrated large molecule analytical platforms, our preeminent knowledge of the chemistry of blood, and our philosophy of “Science with a Sense of Urgency”. Our services and products bridge both Product Development and Clinical domains from discovery to commercial release, and HT has grown into a leading provider of expertise in large molecule analytical chemistry from plasma therapeutics to mAb’s to gene therapies. HT is truly a large molecule CRO unlike any other.